Every year Finance Monthly M&A Awards recognise and celebrate the achievements of dealmakers, management teams, financiers and professional advisers who, over the 12 months, have demonstrated their deal making excellence when working on some of the most important deals across the globe. For 2017 Life Sciences Advisory was selected as the Global Biotech Advisory Firm of the Year.
The Health Innovators Fellowship Program was created in 2015 to strengthen the leadership of innovators across the healthcare ecosystem and to connect, inspire, and challenge them to create new approaches that will improve the health and well-being of our society. The program is modeled on both the Henry Crown Fellowship and the Liberty Fellowship, and building upon the Aspen Institute’s commitment to values-based, action-oriented leadership.
This year’s Dementia Awareness Week runs from 15-21 May and is supported by the Alzheimer’s Society – the UK’s leading support and research charity for people with dementia, their families and carers. The theme this year focuses on encouraging people who are worried about dementia to confront their worries by addressing dementia directly and going to the Alzheimer’s Society for information and support.
CorporateLiveWire recognized Life Sciences Advisory as the top Life Sciences Advisory firm in the USA for 2016 with its M&A Awards.
M&A is on the rise across almost every region. Knock on effects of strengthening global markets mean that international deal valuation is rising, as is the number of deals. 2016 was a fantastic year for mergers and acquisitions globally, with high deal volumes and valuations including the China National Chemical Corp acquisition of Syngenta AG for an enormous $43bn in cash.
Women in Bio (WIB) organized a dynamic panel discussion on “Hot Topics in Life Sciences” examining what’s innovative and exciting in the current field of life sciences. The event was held at Nektar Therapeutics on September 26 in San Francisco. The issues ranged from FDA regulation and innovation barriers to drug adherence and drug repurposing, and WIB members were actively engaging with the speakers and the overall conversation was enlightening and productive.
Current therapies for Parkinson’s disease treat the symptoms but do not prevent, slow or halt its progression. Investigators are on the cusp of discovery and drug development that will improve current symptomatic treatments, allow for earlier diagnosis, and provide the cure for Parkinson’s that millions desperately seek. Genetic insights, characterization of drug targets and coordination of efforts have brought us closer to a disease-modifying therapy.
Since 2010, Acquisition International Magazine's annual awards have been highlighting the amazing work done by those firms and individuals whose ceaseless dedication to innovation, customer care and the continued growth and improvement of their businesses has seen them forge ahead of their competitors and raise the bar for performance and results in their industry.